Literature DB >> 15671196

The company we keep: why physicians should refuse to see pharmaceutical representatives.

Howard Brody1.   

Abstract

Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will act contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counterargument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.

Entities:  

Mesh:

Year:  2005        PMID: 15671196      PMCID: PMC1466797          DOI: 10.1370/afm.259

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  19 in total

1.  A piece of my mind: financial indigestion.

Authors:  J P Kassirer
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

2.  Promotion of prescription drugs to consumers.

Authors:  Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

3.  Physician-industry relations. Part 1: individual physicians.

Authors:  Susan L Coyle
Journal:  Ann Intern Med       Date:  2002-03-05       Impact factor: 25.391

4.  Drug industry is told to stop gifts to doctors.

Authors:  Robert Pear
Journal:  N Y Times Web       Date:  2002-10-01

5.  Are sample medicines hurting the uninsured?

Authors:  John Zweifler; Susan Hughes; Sean Schafer; Bruno Garcia; Angela Grasser; Leticia Salazar
Journal:  J Am Board Fam Pract       Date:  2002 Sep-Oct

6.  Selling drugs by "educating" physicians.

Authors:  C D MAY
Journal:  J Med Educ       Date:  1961-01

7.  Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy.

Authors:  A Schafer
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

8.  The accuracy of drug information from pharmaceutical sales representatives.

Authors:  M G Ziegler; P Lew; B C Singer
Journal:  JAMA       Date:  1995-04-26       Impact factor: 56.272

9.  Doctors, drug companies, and gifts.

Authors:  M M Chren; C S Landefeld; T H Murray
Journal:  JAMA       Date:  1989 Dec 22-29       Impact factor: 56.272

10.  A physician survey of the effect of drug sample availability on physicians' behavior.

Authors:  L D Chew; T S O'Young; T K Hazlet; K A Bradley; C Maynard; D S Lessler
Journal:  J Gen Intern Med       Date:  2000-07       Impact factor: 5.128

View more
  13 in total

1.  General practitioners and pharmaceutical sales representatives: quality improvement research.

Authors:  Geoffrey Spurling; Peter Mansfield
Journal:  Qual Saf Health Care       Date:  2007-08

2.  Use of atypical antipsychotics in nursing homes and pharmaceutical marketing.

Authors:  Camilla B Pimentel; Jennifer L Donovan; Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Abir O Kanaan; Celeste A Lemay; Kathleen M Mazor; Jennifer Tjia; Becky A Briesacher
Journal:  J Am Geriatr Soc       Date:  2015-02       Impact factor: 5.562

3.  Approach to hypertension among primary care physicians in the West Region of Cameroon: substantial room for improvement.

Authors:  Jean Jacques N Noubiap; Ahmadou M Jingi; Sandra Wandji Veigne; Arnold Ewane Onana; Edvine Wawo Yonta; Samuel Kingue
Journal:  Cardiovasc Diagn Ther       Date:  2014-10

4.  Big Pharma: a former insider's view.

Authors:  David Badcott
Journal:  Med Health Care Philos       Date:  2013-05

5.  The characteristics of conflict of interest in the doctor's pharmaceutical representative Relationship.

Authors:  Houda Lajmi; Mokhles Lajmi; Wassim Hmaied
Journal:  Tunis Med       Date:  2022 fevrier

Review 6.  Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.

Authors:  Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry
Journal:  PLoS Med       Date:  2010-10-19       Impact factor: 11.069

7.  Evaluation of rationality of promotional drug literature using World Health Organization guidelines.

Authors:  Smita N Mali; Sujata Dudhgaonkar; N P Bachewar
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

8.  A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?

Authors:  Roberto Cardarelli; John C Licciardone; Lockwood G Taylor
Journal:  BMC Fam Pract       Date:  2006-03-03       Impact factor: 2.497

9.  Knowledge, attitude and skills before and after a module on pharmaceutical promotion in a Nepalese medical school.

Authors:  P Ravi Shankar; Kundan K Singh; Rano M Piryani
Journal:  BMC Res Notes       Date:  2012-01-06

10.  Modern Practice Era: The Purpose of Physician's Sample.

Authors:  Sugam A Bhatnagar; Jagannath V Dixit
Journal:  Indian J Community Med       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.